$ABBV

Bristol Myers Squibb, AbbVie, and Boehringer Ingelheim are seeking to intervene in a lawsuit challenging a federal drug rebate pilot program. The companies argue the US Health Resources & Services Administration cannot fully defend their interests in the 340B Rebate Model Pilot, set to launch January 1, 2025. The program aims to change how manufacturers discount certain medicines under the 340B Drug Pricing Program.

AbbVie presented phase 3 study data at the 2026 EADV Congress, showing Rinvoq (upadacitinib) demonstrated continued facial and body repigmentation in non-segmental vitiligo through week 76. The data also included week-28 findings from a phototherapy substudy, where Rinvoq combined with NB-UVB phototherapy showed higher repigmentation responses than Rinvoq alone. Rinvoq is approved in the EU for NSV treatment and is under FDA review in the US.

Novo Nordisk reported 2025 revenue of $46.3B (+6.4% YoY) and net income of $15.3B (33.1% margin). It faces competition and pricing pressures. AbbVie's Skyrizi and Rinvoq drove 42% of 2025 sales, but it faces pricing pressures and litigation. Both companies have growth prospects and challenges. Analysts debate their long-term outlooks.

AbbVie presented Phase 3 AFFIRM study results showing subcutaneous SKYRIZI® (risankizumab-rzaa) achieved higher endoscopic remission and ulcer-free endoscopy rates in Crohn's disease patients vs. placebo. The data supports FDA approval for a new induction dosing regimen. SKYRIZI is already approved for other immune-mediated diseases.

AbbVie (ABBV) announced a phase 2 trial for telisotuzumab adizutecan combined with pembrolizumab to treat head and neck cancer. The study compares two doses of the combo against standard chemotherapy, aiming to establish safety, efficacy, and potential regulatory approval. The trial is ongoing and recruiting, with primary completion expected in 2027. Success could boost ABBV's long-term growth prospects in oncology.

RBC Capital maintained an 'Outperform' rating on AbbVie (ABBV) with a $280 price target. GuruFocus values ABBV at $222.10, suggesting a 25.4% overvaluation. The company has a GF Score of 76, indicating strong profitability but weaker financial strength and momentum. Insiders sold $8.18M in shares over three months. Analysts' price targets range from $275 to $310.

Netflix (NFLX) was recommended by Stephen Weiss, with Morgan Stanley lowering its price target to $80. AbbVie (ABBV) was picked by Jim Lebenthal, following FDA designations. DocuSign (DOCU) was highlighted by Jenny Harrington, after reporting strong Q2 results with $875.75M revenue and $1.16 EPS.

Biotech stocks are rebounding due to record pharmaceutical M&A deals, with 37 acquisitions worth at least $1B each in 2026, totaling $216B. Key deals include Vertex (VRTX) acquiring Crinetics (CRNX) for $10B. Institutional investors are bullish, but retail sentiment is low. The Direxion Biotech Bull 3x Shares (LABU) fund has gained 52.5% YTD, despite its index being down last week.

AbbVie (ABBV) trades at $277.15, with a 12-month price target of $279.12 (2.46% upside). Q2 revenue rose 10.2% to $16.99B, and EPS met estimates. Management raised revenue guidance to $67.6B. Skyrizi and Rinvoq showed strong growth, while Humira sales declined. The stock has gained 24.16% YTD, breaking its 52-week high. Analysts see potential upside to $297.77, but risks include Humira erosion and debt.

Several biotech stocks reached 52-week highs on October 9, 2026. Humana (HUM) rose 11% to $456.50, driven by improved Medicare Advantage ratings. Puma Biotechnology (PBYI) gained 3% to $10.10, while AbbVie (ABBV) hit $274.94. Moderna (MRNA) surged 14% to $225 after positive clinical trial results. AVITA Medical (RCEL) climbed to $13.71, reporting 18% revenue growth in Q2 2026.